Evidence map›Paper›PMID 26883431›Full record

ReviewCurrent neurology and neuroscience reports2016

Neuroprotection Trials in Traumatic Brain Injury.

Shamik Chakraborty, Brett Skolnick, Raj K Narayan

Abstract readReview
PubMed Publisher
In one paragraph

Review in Current neurology and neuroscience reports, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 24 papers.

0numbers the graph read from it
0cells of the map it votes in
24citing papers in PubMed
5.8field-weighted citation impact, top 4% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

24 citing papers in PubMed, 49 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Role of Citicoline in the Management of Traumatic Brain Injury.Pharmaceuticals (Basel, Switzerland) · 2021
    Review
  10. Hyaluronidase reduced edema after experimental traumatic brain injury.Journal of cerebral blood flow and metabolism : official journal of the International Society of Cerebral Blood Flow and Metabolism · 2020
    Article
  11. Review
  12. Article
  13. Article
  14. Review
  15. Article
  16. Article
  17. Article
  18. Review
  19. Therapeutic potential of vitamin E and its derivatives in traumatic brain injury-associated dementia.Neurological sciences : official journal of the Italian Neurological Society and of the Italian Society of Clinical Neurophysiology · 2018
    Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors at 1 institution in 1 country.

Shamik ChakrabortyDepartment of Neurosurgery, Hofstra Northwell School of Medicine, 300 Community Drive, 9 Tower, Manhasset, NY, 11030, USA. schakraborty@northwell.edu.
Brett SkolnickDepartment of Neurosurgery, Hofstra Northwell School of Medicine, 300 Community Drive, 9 Tower, Manhasset, NY, 11030, USA. BSkolnick2@northwell.edu.
Raj K NarayanDepartment of Neurosurgery, Hofstra Northwell School of Medicine, 300 Community Drive, 9 Tower, Manhasset, NY, 11030, USA. RNarayan@northwell.edu.
Hofstra University · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Traumatic brain injury (TBI) is a significant cause of mortality and morbidity worldwide. Current treatment of acute TBI includes surgical intervention when needed, followed by supportive critical care such as optimizing cerebral perfusion, preventing pyrexia, and treating raised intracranial pressure. While effective in managing the primary injury to the brain and skull, these treatment modalities do not address the complex secondary cascades that occur at a cellular level following initial injury and greatly affect the ultimate neurologic outcome. These secondary processes involve changes in ionic flux, disruption of cellular function, derangement of blood flow and the blood-brain barrier, and elevated levels of free radicals. Over the past few decades, numerous pharmacologic agents and modalities have been investigated in an attempt to interrupt these secondary processes. No neuroprotective agents currently exist that have been proven to improve neurologic outcome following TBI. However, these trials have contributed significantly to the understanding of the clinical sequelae of TBI and to improvements in the quality of care for TBI. With the experience and insights that have been accrued with the trials to date, we will be able to optimize future trial designs and refine established neurologic endpoints to better identify new therapeutic agents and further improve neurologic outcomes from this often devastating condition.

Indexed as

Clinical Trials as TopicNeuroprotectionAnimalsBlood-Brain BarrierBrain InjuriesHumansNeuroprotective AgentsNeuroprotective AgentsClinical trialsNeuroprotectionTraumatic brain injury

Identifiers

PMID26883431
OpenAlexW2276812133

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.